ANVS

Annovis Bio
ANVS

Last Price

Financial Snapshot

gainify

Market Data

Market Cap
$48.93M
EV
$31.80M
Shares Outstanding
23.30M
Beta
1.61
Industry
Biotechnology

Wall Street View

Analyst Rating
OUTPERFORM
Analyst Target Price
Number of Analysts
4
P/E 2025E
-
P/Revenue 2025E
-

Price Dynamic

Price

%

1M

3M

6M

1Y

3Y

5Y

Peers

gainify

About Annovis Bio, Inc.

gainify
ANVS

Annovis Bio, Inc.

ANVS

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company’s lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer’s disease (AD), Parkinson’s dis...

Sector

Healthcare

Industry

Biotechnology

CEO

Maccecchini, Maria

Employees

12

IPO Date

2020-01-29

Headquarters

101 Lindenwood Drive, Suite 225, Malvern, Pennsylvania, 19355, United States

gainifypowered-by-sp
Socials
Send us an emailFollow us on XConnect with us on LinkedInFollow us on InstagramFollow us on ThreadsCheck us out on TrustpilotFollow us on YouTubeFind us on Google Maps

Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright © 2025, S&P Global Market Intelligence. All rights reserved.

View Data Providers

NEWSLETTER

Gainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.

© 2025 Gainify. All rights reserved.